IN2013MN00441A - - Google Patents

Info

Publication number
IN2013MN00441A
IN2013MN00441A IN441MUN2013A IN2013MN00441A IN 2013MN00441 A IN2013MN00441 A IN 2013MN00441A IN 441MUN2013 A IN441MUN2013 A IN 441MUN2013A IN 2013MN00441 A IN2013MN00441 A IN 2013MN00441A
Authority
IN
India
Prior art keywords
peptide
keratin
glucagon
type
assays
Prior art date
Application number
Inventor
Joseph Anderberg
Jeff Gray
Paul Mcpherson
Kevin Nakamura
James Patrick Kampf
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of IN2013MN00441A publication Critical patent/IN2013MN00441A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

The present invention relates to methods and compositions for monitoring diagnosis prognosis and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Beta nerve growth factor Interleukin 17A Follitropin subunit beta Collagenase 3 Follistatin Vitamin D Binding Protein Islet amyloid polypeptide Insulin C peptide Complement Factor H Gastric inhibitory polypeptide Glucagon like peptide 1 Glucagon Involucrin Type II cytoskeletal Keratin 1/Keratin 10 Type II cytoskeletal Keratin 6 A/6B/6C Osteocalcin Lipopolysaccharide Pancreatic prohormone Peptide YY Agouti related protein Ciliary neurotrophic factor Appetite regulating hormone Transthyretin Insulin receptor substrate 1 and NF kappa B inhibitor alpha as diagnostic and prognostic biomarker assays in renal injuries.
IN441MUN2013 2010-10-07 2011-10-06 IN2013MN00441A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39099910P 2010-10-07 2010-10-07
PCT/US2011/055055 WO2012048082A2 (en) 2010-10-07 2011-10-06 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
IN2013MN00441A true IN2013MN00441A (en) 2015-05-29

Family

ID=45928428

Family Applications (1)

Application Number Title Priority Date Filing Date
IN441MUN2013 IN2013MN00441A (en) 2010-10-07 2011-10-06

Country Status (12)

Country Link
US (1) US20130316370A1 (en)
EP (2) EP3249402A1 (en)
JP (3) JP2013539861A (en)
CN (1) CN103238068B (en)
AU (1) AU2011311997A1 (en)
CA (1) CA2811438A1 (en)
EA (1) EA201390293A1 (en)
HK (1) HK1186248A1 (en)
IN (1) IN2013MN00441A (en)
MX (1) MX2013003662A (en)
NZ (1) NZ608316A (en)
WO (1) WO2012048082A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10794917B2 (en) * 2013-09-20 2020-10-06 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
CA2939366A1 (en) * 2014-02-20 2015-08-27 Immundiagnostik Ag In vitro diagnostic and prognosis of contrast induced nephropathy (cin) in patients undergoing coronary angiography
US11506672B2 (en) 2015-06-11 2022-11-22 Astute Medical, Inc. Follistatin-related protein 3 for diagnosis and prognosis of renal injury and renal failure
CN106405064B (en) * 2016-08-30 2018-10-26 嘉兴行健生物科技有限公司 A kind of appraisal procedure of 40 years old or more women bone turnover rate
KR102432962B1 (en) * 2017-03-16 2022-08-12 쉔첸 인스티튜트스 오브 어드밴스드 테크놀로지 Polypeptides modulating energy metabolism and uses thereof
CN109468357A (en) * 2018-12-25 2019-03-15 河北肽都生物科技有限公司 A kind of preparation method of spleen aminopeptide
WO2021018774A1 (en) * 2019-07-26 2021-02-04 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Ergothioneine, s-methyl-ergothioneine, and uses thereof
CN113092768A (en) * 2019-12-23 2021-07-09 首都医科大学附属北京世纪坛医院 Application of urine keratin, II type cytoskeleton 1 and polypeptide fragment thereof in allergic diseases
CN114264828B (en) * 2022-01-28 2023-09-08 中国科学院基础医学与肿瘤研究所(筹) Biomarker for identifying benign thyroid nodule and thyroid cancer and application thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
AU658374B2 (en) 1990-09-14 1995-04-13 Biosite Diagnostics Incorporated Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
EP0585310B1 (en) 1991-04-10 1999-03-17 Biosite Diagnostics Inc. Crosstalk inhibitors and their uses
ES2150915T3 (en) 1991-04-12 2000-12-16 Biosite Diagnostics Inc NEW CONJUGATES AND DOSES INTENDED FOR THE SIMULTANEOUS DETECTION OF MULTIPLE LEAGUES.
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
JP4487376B2 (en) * 2000-03-31 2010-06-23 味の素株式会社 Kidney disease treatment
JP2002191398A (en) * 2000-12-26 2002-07-09 Jenokkusu Soyaku Kenkyusho:Kk Method for examining allergic disease
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20030224386A1 (en) * 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
WO2005000194A2 (en) * 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
US6941172B2 (en) * 2002-11-18 2005-09-06 Zvi Nachum Method and device for restoring kidney function using electromagnetic stimulation
JP2007532889A (en) * 2004-04-16 2007-11-15 モナシュ ユニバーシティー How to monitor cancer progression
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
FR2872579B1 (en) * 2004-06-30 2006-11-24 Pasteur Institut DETECTION OF TUBERCULOSIS AND MYCOBACTERIUM TUBERCULOSIS INFECTION USING HBHA
EP1839057B1 (en) * 2004-12-15 2010-08-25 Beth Israel Deaconess Medical Center Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy
ES2818028T3 (en) * 2004-12-20 2021-04-09 Antibodyshop As Determination of lipocalin associated with neutrophil gelatinase (NGAL) as a diagnostic marker for kidney disorders
US20070087387A1 (en) * 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
JP2007057509A (en) * 2005-08-26 2007-03-08 Toray Ind Inc Method of measuring cat activin a, and measuring kit
US7623910B2 (en) * 2006-03-10 2009-11-24 University Of Rochester ECG-based differentiation of LQT1 and LQT2 mutation
JP2009531332A (en) * 2006-03-23 2009-09-03 ライフ テクノロジーズ コーポレーション Methods and reagents for in vivo imaging of cancer cell lines
US7662578B2 (en) * 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US20090047694A1 (en) * 2007-08-17 2009-02-19 Shuber Anthony P Clinical Intervention Directed Diagnostic Methods
ES2397484T3 (en) * 2007-03-26 2013-03-07 Novartis Ag Predictive biomarkers of renal safety and biomarker signatures to monitor renal function
WO2008150488A1 (en) * 2007-06-01 2008-12-11 Laboratory Corporation Of America Holdings Methods and systems for quantification of peptides and other analytes
US8039227B2 (en) * 2007-09-20 2011-10-18 University Of Louisville Research Foundation, Inc. Peptide biomarkers predictive of renal function decline and kidney disease
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
WO2010057184A2 (en) * 2008-11-17 2010-05-20 The Brigham And Women's Hospital, Inc. Methods for detection of acute kidney injury in humans
NZ604873A (en) * 2008-11-22 2014-05-30 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ594771A (en) * 2009-02-06 2013-06-28 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and failure
JP5981144B2 (en) * 2009-02-06 2016-08-31 アスチュート メディカル，インコーポレイテッド Diagnosis and prognosis of kidney damage and renal failure
US9029093B2 (en) * 2010-02-26 2015-05-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Also Published As

Publication number Publication date
WO2012048082A2 (en) 2012-04-12
CN103238068A (en) 2013-08-07
CN103238068B (en) 2016-06-08
US20130316370A1 (en) 2013-11-28
JP2013539861A (en) 2013-10-28
NZ608316A (en) 2015-03-27
JP6321080B2 (en) 2018-05-09
WO2012048082A3 (en) 2012-06-21
CA2811438A1 (en) 2012-04-12
MX2013003662A (en) 2013-05-01
EP2625524A4 (en) 2014-05-07
EP3249402A1 (en) 2017-11-29
AU2011311997A1 (en) 2013-04-04
HK1186248A1 (en) 2014-03-07
JP2018141793A (en) 2018-09-13
EP2625524A2 (en) 2013-08-14
EA201390293A1 (en) 2013-09-30
JP2016180762A (en) 2016-10-13

Similar Documents

Publication Publication Date Title
IN2013MN00441A (en)
Diedisheim et al. Modeling human pancreatic beta cell dedifferentiation
Chartoumpekis et al. Nrf2 represses FGF21 during long-term high-fat diet–induced obesity in mice
Hackett et al. The human airway epithelial basal cell transcriptome
Takahashi et al. SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver
Li et al. Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand
Atkinson et al. C9ORF72 expression and cellular localization over mouse development
Cai et al. Indispensable role of the Ubiquitin-fold modifier 1-specific E3 ligase in maintaining intestinal homeostasis and controlling gut inflammation
Makki et al. Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice
BR112012007365A2 (en) il-1 binding proteins
Barbosa-da-Silva et al. Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice
Kuo et al. Induction of α cell–restricted Gc in dedifferentiating β cells contributes to stress-induced β cell dysfunction
TW200726845A (en) Biomarker molecular of renal illness and detecting method for the same
WO2008060607A3 (en) Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
Camilleri et al. Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion
NZ629074A (en) Biomarkers for gastric cancer and uses thereof
Dobarro et al. Propranolol reduces cognitive deficits, amyloid β levels, tau phosphorylation and insulin resistance in response to chronic corticosterone administration
MX343167B (en) Methods and compositions for identifying and treating lupus.
Yamane et al. Mechanisms of fat‐induced gastric inhibitory polypeptide/glucose‐dependent insulinotropic polypeptide secretion from K cells
WO2009101059A3 (en) Methods of using cadherin 11 (cdh11) antagonists
WO2009019365A3 (en) Ezrin assay method for the in vitro diagnosis of colorectal cancer
Liu et al. Expression of somatostatin receptor 2 in somatotropinoma correlated with the short-term efficacy of somatostatin analogues
Cabezas et al. Participation of the SMAD2/3 signalling pathway in the down regulation of megalin/LRP2 by transforming growth factor beta (TGF-ß1)
BR112013021056A2 (en) monoclonal antibody, hybridoma cell line, diagnostic kit, methods for producing a monoclonal antibody and binding agent, purified amino acid sequence binding agent, method for obtaining a coding nucleic acid sequence, antibody molecule encoding isolated nucleic acid, vector, isolated host cell, fusion protein, screening method for the presence of a disease, a condition, methods of diagnosing an individual, prognosis for an individual, and monitoring an individual, and , method for detecting the presence or absence of cervical cancer
Auinger et al. Human intestinal fatty acid binding protein 2 expression is associated with fat intake and polymorphisms